NOS2 isn't good for ER-negative breast cancer patients, study finds

Breast cancers can be divided into different subtypes. Patients with breast tumors that lack expression of the protein ER (ER-negative breast tumors) have a worse outlook than those with ER-positive breast tumors. Among ER-negative breast tumors, those characterized as basal-like are the most aggressive and difficult to treat. New therapeutic targets for this breast cancer subtype are urgently needed. New research suggests that the protein NOS2 could be a good drug target in this context.

Read the whole article on Science Daily

More from Science Daily